×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: cholesterol | injection | medication | Leqvio | siRNA | inclisiran

FDA Approves Twice-Yearly Injection to Lower Cholesterol

Clipboard with what high different categories of high LDL cholesterol
(Dreamstime)

By    |   Tuesday, 28 December 2021 08:12 AM

The Food and Drug Administration (FDA) recently approved a novel injectable cholesterol-lowering drug to be used as an adjunct to diet and statin medication. The Novartis drug, Leqvio, is the first small interfering RNA (siRNA) therapy to reduce LDL cholesterol, the low-density lipoprotein dubbed “bad” cholesterol because it can contribute to arterial blockage.

According to MedPage Today, Leqvio, generic name inclisiran, is injected subcutaneously, followed by a second shot at three months and then a maintenance dose every six months thereafter. The drug is geared for patients who have clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia who need to lower their levels of LDL.

Leqvio will be available in early January. European regulators already approved the siRNA at the end of 2020.

The most common side effects, according to MedPage, were mild-to-moderate injection site reaction, joint pain, urinary tract infection, diarrhea, chest cold, pain in the legs or arms, and shortness of breath. The clinical trials already performed did not determine whether or not the drug reduces death from cardiovascular disease. More studies are underway.

Approximately 16 million Americans with ASCVD taking statins to lower their cholesterol — including those who have already had a heart attack or stroke — are not at their recommended LDL target. According to Novartis, Leqvio provides effective and sustained reduction of LDL up to 52% versus a placebo for certain people with ASCVD who already take the maximum tolerated statin therapy.

“ASCVD is a substantial public health burden affecting 30 million Americans,” said Norman Lepor, a Los Angeles-based cardiologist, and a clinical investigator in the Phase III clinical program for Leqvio. “As a first-of-its-kind siRNA therapy, Leqvio works differently than other cholesterol treatments, with twice-yearly dosing that makes it a compelling option for the millions of people with ASCVD already on cholesterol-lowering medications struggling to meet their LDL-C target.”

© 2022 NewsmaxHealth. All rights reserved.


Health-News
The Food and Drug Administration (FDA) recently approved a novel injectable cholesterol-lowering drug to be used as an adjunct to diet and statin medication. The Novartis drug, Leqvio, is the first small interfering RNA (siRNA) therapy to reduce LDL cholesterol, the...
cholesterol, injection, medication, Leqvio, siRNA, inclisiran
307
2021-12-28
Tuesday, 28 December 2021 08:12 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved